Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease

Liver International

Volumn 34, Issue 10, 2014, Pages 1488-1495

  Næss, Sigrid ^a,b,c   Björnsson, Einar ^d   Anmarkrud, Jarl A ^a,c   Mamari, Said Al ^e,f   Juran, Brian D ^g   Lazaridis, Konstantinos N ^g   Chapman, Roger ^h   Bergquist, Annika ⁱ   Melum, Espen ^a,b,c   Marsh, Steven G E ^j   Schrumpf, Erik ^a   Lie, Benedicte A ^b,c   Boberg, Kirsten M ^a,b,c   Karlsen, Tom H ^a,b,c,k   Hov, Johannes R ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f SULTAN QABOOS HOSPITAL   (Oman)

^g MAYO CLINIC   (United States)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j ROYAL FREE HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BERGEN   (Norway)

more..

Author keywords

Human leucocyte antigens; Inflammatory bowel disease; Large duct; Primary sclerosing cholangitis; Small duct

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DRB1 ANTIGEN; HLA B8 ANTIGEN; HLA-DRB1*13:01 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HISTOCOMPATIBILITY GENE; HLA SYSTEM; HUMAN; INFLAMMATORY BOWEL DISEASE; LARGE DUCT PRIMARY SCLEROSING CHOLANGITIS; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; RISK ASSESSMENT; SMALL DUCT PRIMARY SCLEROSING CHOLANGITIS; CLASSIFICATION; COMPARATIVE STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; NORWAY; PHENOTYPE; RISK; RISK FACTOR; SCLEROSING CHOLANGITIS; SWEDEN; UNITED KINGDOM; UNITED STATES;

CHOLANGITIS, SCLEROSING; GENOTYPE; GREAT BRITAIN; HLA-B8 ANTIGEN; HLA-DRB1 CHAINS; HUMANS; INFLAMMATORY BOWEL DISEASES; LINKAGE DISEQUILIBRIUM; NORWAY; ODDS RATIO; PHENOTYPE; RISK FACTORS; SWEDEN; UNITED STATES;

EID: 84908123401     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12492     Document Type: Article

References (36)

1. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013; 382: 1587-99.
2. Bjornsson E. Small-duct primary sclerosing cholangitis. Curr Gastroenterol Rep 2009; 11: 37-41.
3. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007; 102: 1042-9.
4. Lai J, Taouli B, Iyer KR, et al. Cholangiolocellular carcinoma in a pediatric patient with small duct sclerosing cholangitis: a case report. Semin Liver Dis 2012; 32: 360-6.
5. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35: 1494-500.
6. Bjornsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51: 731-5.
7. Broome U, Glaumann H, Lindstom E, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002; 36: 586-9.
8. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134: 975-80.
9. European Association for the Study of the L. EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
10. Gotthardt D, Runz H, Keitel V, et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 2008; 48: 1157-66.
11. Ziol M, Barbu V, Rosmorduc O, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008; 135: 131-41.
12. Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6: 939-43.
13. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138: 1102-11.
14. Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43: 17-9.
15. Folseraas T, Melum E, Rausch P, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012; 57: 366-75.
16. Liu JZ, Hov JR, Folseraas T, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013; 45: 670-5.
17. Schrumpf E, Fausa O, Forre O, et al. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982; 17: 187-91.
18. Spurkland A, Saarinen S, Boberg KM, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53: 459-69.
19. Donaldson PT, Farrant JM, Wilkinson ML, et al. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991; 13: 129-33.
20. Hov JR, Lleo A, Selmi C, et al. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol 2010; 52: 712-7.
21. Farrant JM, Doherty DG, Donaldson PT, et al. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992; 16: 390-5.
22. Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002; 35: 555-64.
23. Wiencke K, Karlsen TH, Boberg KM, et al. Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes. Tissue Antigens 2007; 69: 161-9.
24. Karlsen TH, Boberg KM, Olsson M, et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 2007; 46: 899-906.
25. Karlsen TH, Boberg KM, Vatn M, et al. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun 2007; 8: 275-8.
26. Thomson G. Mapping disease genes: family-based association studies. Am J Hum Genet 1995; 57: 487-98.
27. Hov JR, Kosmoliaptsis V, Traherne JA, et al. Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology 2011; 53: 1967-76.
28. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11: 116-28.
29. Hor H, Kutalik Z, Dauvilliers Y, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 2010; 42: 786-9.
30. Rojas-Villarraga A, Botello-Corzo D, Anaya JM. HLA-Class II in Latin American patients with type 1 diabetes. Autoimmun Rev 2010; 9: 666-73.
31. van der Woude D, Lie BA, Lundstrom E, et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 2010; 62: 1236-45.
32. Hohler T, Gerken G, Notghi A, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997; 26: 503-7.
33. Mackie SL, Taylor JC, Martin SG, et al. A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. Genes Immun 2012; 13: 120-8.
34. Maniaol AH, Elsais A, Lorentzen AR, et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS ONE 2012; 7: e36603.
35. Karlsen TH, Hov JR. Genetics of cholestatic liver disease in 2010. Curr Opin Gastroenterol 2010; 26: 251-8.
36. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865-72.